🚨 TACE + TKIs +/- SBRT OS (17.93 vs. 9.61 months, HR=1.869 [95%CI, 1.059-3.266], P=0.017) Survival benefit with SBRT #asco2024

Our manuscript "Optimal management of radiation pneumonitis" is now in Lung Cancer Journal Delphi consensus amongst 🌎oncology & 🫁 experts re: ▶️RP risk stratification ▶️☢️Planning ▶️Diagnosis & Management ▶️Grey zones with 💊induced pneumontis lungcancerjournal.info/article/S0169-… Alex Louie MD, PhD

🚨🚨🚨TRANSMET🚨🚨🚨 WOW! RCT patients with unresectable liver-only metastasis Chemotherapy alone Vs Chemotherapy + liver transplantation ✅significant improvement in median and long term survival with LT #ASCO24

The ULTRAS trial will shortly start recruiting patients with liver metastases led by Dr Ali Hosni from Princess Margaret Hospital, Toronto. The clinical hypothesis being investigated is whether a higher single dose of MRgRT improves local control in patients with liver mets

Our ph1 trial on MR-guided focused US for radiosensitization is out Radiotherapy & Oncology - 11 HN cancer pts - FUS + curative or palliative RT - Treatment was safe - Sustained complete responses observed Great work by Dr Czarnota Lab and RT team Sunnybrook Health Sciences Centre thegreenjournal.com/article/S0167-…

Efficacy of stereotactic ablative radiotherapy in oligometastatic HCC Journal of Hepatology doi.org/10.1016/j.jhep… 🔎phase II study 🇰🇷 👉2-yr OS 80% 👉mPFS 5.3 mo, 1 yr PFS 21.2% 👉ORR & DCR 75.9 & 98.4% 🧐effective & feasible option for oligometastatic HCC ESMO - Eur. Oncology EASLnews ILCA

Hot off the press in IJROBP - The Red Journal: the ARREST phase I trial of SABR in poly-metastatic disease, led by Glenn Bauman, MD & Tim Nguyen Average number of lesions = 16 Dose safely escalated to 30 Gy in 5 fractions. sciencedirect.com/science/articl… The phase II/III RCT ARREST2 is underway!

Great to see this out- congrats Yaacov Lawrence Md, Laura Dawson et al. Retroperitoneal pain due to tumor celiac plexus involvement can be debilitating & narcotic refractory 25 Gy x 1 improving pain in 53% is remarkable! RCT of RT v celiac block hopefully forthcoming NRG Oncology🤞1/3

Pleased to speak with Sue Yom (IJROBP - The Red Journal Editor) on the Red Journal podcast about #proton therapy access in the US 🇺🇸and globally 🌍 - we are still waiting for domestic access to this technology in Ontario/Canada! Listen here: redjournal.org/audio-do/red-j…☢️

🔬 Our MA confirms SBRT's safety & efficacy for non-spine bone mets . 💪 Low 1-year local failure (7%) & fracture (5.3%) rates. 📊 Target volume planning reduces fracture risk. #CancerTreatment #RadiationOncology ASTRO IJROBP - The Red Journal Andre G, MD, Rad Onc 🇧🇷 🇮🇹 🇨🇦 Gustavo Michael Yan, MD MPH

This is a super high yield case-based paper on pancreas SBRT - many technique pearls & great review of recent trials. Highly rec for trainees/any rad oncs treating pancreas! Awesome work Michael Chuong Baho Sidiqi Terry Williams Percy Lee MD et al! practicalradonc.org/article/S1879-…

It was great learning about your innovative work in VR and applications to education locally and internationally. Thanks for visiting Humza Nusrat, Ph.D.!

Congrats Ethan Ludmir MD and Chad Tang, MD! This MD Anderson Cancer Center P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer ascopubs.org/doi/10.1200/JC…

Letter to editor from Laura Dawson Jordan Kharofa Dr. Nina Niu Sanford Ali Hosni Mamen Rubio Rodriguez Regarding 1.5 T MRL pancreas planning protocol manuscript (PMID 38831754) Elective coverage should be routine It impacts planning authors.elsevier.com/sd/article/S24…

It was a pleasure hosting Danielle Bitterman, MD as visiting professor this week at Radiation Medicine Program. Exciting, innovative research in applications of LLMs in oncology, a thought leader in the field. #MachineLearning #LLMs #radonc Harvard Radiation Oncology Residency Program UofT Radiation Oncology Residents

New clinical guideline for challenging spine cases. I have the pleasure of working with the leaders in the field! Thanks for the leadership Kristin Redmond Simon Lo Amazing support from arjun sahgal Shankar Siva Matthias Guckenberger Joshua D. Palmer, MD Eric Chang et al

Very important study and treatment option for patients in pain. Survival signal is interesting, and followup trial in the works... Laura Dawson Radiation Medicine Program

🚨 New Insights into Patterns of Locoregional Recurrence in #PancreaticCancer after TNT & Their Impact on Neoadjuvant RT Volumes 🚨 pubmed.ncbi.nlm.nih.gov/39182645/ #PancSM #Radonc 🙌 Sara Beltrán Ponce, MD n=1/8

Pleased to bring gallium-68 PET imaging to guide precision #radiation for patients with #meningioma, a type of benign brain tumour University Health Network Radiation Medicine Program uhn.ca/corporate/news…

PANDAS-PRODIGE 44 mFOLFIRINOX +/- chemoRT (50.4 Gy) in borderline resectable pancreas cancer. No dif in R0 resection (1 endpt) or OS for all comers…but pCR for chemoRT group was 29% (vs. 8%) & OS improved w chemoRT for pts undergoing resection (48 vs. 36 months). #ESMO24